Optimizing Multiple Myeloma Treatment: Quadruplet Therapy

EP: 1.Unmet Needs In Multiple Myeloma Management

EP: 2.Evolving Goals in Multiple Myeloma Treatment

EP: 3.Multiple Myeloma Induction Challenges and Future Options

Now Viewing

EP: 4.Optimizing Multiple Myeloma Treatment: Quadruplet Therapy

EP: 5.Real-World Insights: Multiple Myeloma Treatment Challenges

EP: 6.Navigating the Multiple Myeloma Treatment Landscape

EP: 7.Real-world Multiple Myeloma Treatment: Insights and Challenges

EP: 8.The Future of Multiple Myeloma Treatment

EP: 9.ASH 2023: Multiple Myeloma's Shifting Landscape: Trials and Clinical Perspectives

EP: 10.Multiple Myeloma Frontline Horizon: Quads, Bispecifics, and Breakthroughs

This is a video synopsis/summary of a Peer Exchange featuring Joshua Richter, MD; Rafat Abonour, MD; Faith Davies, MD; and Amrita Krishnan, MD.

Richter discusses the role of K-based quadruplets for myeloma patients, referencing studies such as the PERSEUS trial (NCT03710603). Abonour emphasizes considering carfilzomib as a stronger proteasome inhibitor for high-risk and younger patients. Krishnan offers a contrarian view based on PERSEUS data, questioning the necessity of Krd (carfilzomib, lenalidomide, dexamethasone)-based regimens for all high-risk patients. The discussion extends to consolidation and long-term maintenance strategies, with Abonour highlighting the importance of correctly identifying high-risk patients and expressing interest in data on consolidation in ultra high-risk cases. Richter raises the question of continuing K beyond 2 years in maintenance, considering patient preferences and minimal residual disease dynamics. The panel contemplates a future app for personalized maintenance decisions.

Video synopsis is AI-generated and reviewed by AJMC^® editorial staff.